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Abstract
Antimicrobial peptides encompass a wide variety of structural motifs. Many peptides have K-helical structures. The
majority of these peptides are cationic and amphipathic but there are also hydrophobic K-helical peptides which possess
antimicrobial activity. In addition, some L-sheet peptides have antimicrobial activity and even antimicrobial K-helical
peptides which have been modified to possess a L-structure retain part of their antimicrobial activity. There are also
antimicrobial peptides which are rich in a certain specific amino acid such as Trp or His. In addition, antimicrobial peptides
exist with thio-ether rings, which are lipopeptides or which have macrocyclic Cys knots. In spite of the structural diversity, a
common feature of the cationic antimicrobial peptides is that they all have an amphipathic structure which allows them to
bind to the membrane interface. Indeed, most antimicrobial peptides interact with membranes and may be cytotoxic as a
result of disturbance of the bacterial inner or outer membranes. Alternatively, a necessary but not sufficient property of these
peptides may be to be able to pass through the membrane to reach a target inside the cell. The interaction of these peptides
with biological membranes is not just a function of the peptide but is also modulated by the lipid components of the
membrane. It is not likely that this diverse group of peptides has a single mechanism of action, but interaction of the peptides
with membranes is an important requirement for most, if not all, antimicrobial peptides. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Organisms from throughout the phylogenetic tree,
including animals [1], produce substances for protec-
tion against microbes. Many of these substances are
peptides. With the growing problem of pathogenic
organisms which are resistant to conventional anti-
biotics, there is increased interest in the pharmaco-
logical application of antimicrobial peptides to treat
infection. E¡orts are currently underway to increase
the potency and speci¢city of these peptides so that
they are toxic to microbes and not to mammals. In
order to achieve this in an e⁄cient manner, it is
important to understand the mechanism of action
of these agents and the reason for their selectivity
against microbes.
Even limiting consideration of antimicrobial
agents to peptides, there is still a large variety of
structures known. This makes the task for designing
improved agents more complex, but at the same
time, it provides a range of opportunities for further
development. The classi¢cation of antimicrobial pep-
tides is somewhat arbitrary and there exist analogs
with similar sequences but di¡erent conformational
motifs which would fall into di¡erent classes, despite
the similarity of their chemical structure and possibly
also of their mechanism of action. Nevertheless, to
simplify the problem and to illustrate the range of
structures of peptides with antimicrobial activities,
we have divided these peptides into groups. These
groups include linear peptides which form amphi-
pathic and hydrophobic helices, cyclic peptides and
small proteins which form L-sheet structures, pep-
tides with unique amino acid compositions, cyclic
peptides with thio-ether groups in the ring, lipopep-
tides terminating in an amino alcohol and macro-
cyclic knotted peptides. We will discuss what is
known about the structure and the mechanism of
action of each of these classes of antimicrobial pep-
tides individually.
In general, the mechanism of action of any of
these agents is not very well established. For many
of these peptides, there is evidence that one of the
targets for the peptide is the lipid bilayer of the mem-
brane. This is because these peptides can often in-
crease the rate of leakage of the internal aqueous
contents of liposomes. In addition, most of the anti-
microbial peptides are cationic and their interaction
with anionic phospholipids would provide a ready
explanation for their speci¢city for bacterial mem-
branes. In Gram-negative bacteria, both the outer
lea£et of the plasma membrane as well as the outer
membrane contain anionic molecules oriented to-
wards the exterior of the cell. This is not the case
for mammalian membranes. Hence, the cationic anti-
microbial peptides will preferentially bind to the ex-
posed negative charges of bacterial membranes, but
not to the zwitterionic amphiphiles present in the
extracellular monolayer of mammalian plasma mem-
branes. This speci¢city for anionic membrane com-
ponents is also mimicked in model liposome studies.
There is uncertainty, however, about how these pep-
tides perturb the membrane and whether this mem-
brane perturbation is related to the antimicrobial ac-
tivity of these peptides. It has recently been shown
that there is not always a correlation between the
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ability of peptides to permeabilize membranes and
their antimicrobial activity [2]. It is possible that
the membrane e¡ects of these peptides are not di-
rectly related to their mechanism of cytotoxic action
but rather simply the manner by which they enter the
cell to reach an alternative target [2].
With regard to the mechanism by which the pep-
tide breaks down the membrane permeability barrier,
it is possible that the peptide induces complete lysis
of the organism by rupture of the membrane or that
it perturbs the membrane lipid bilayer, which allows
for leakage of certain cellular components as well as
dissipating the electrical potential of the membrane.
For example, the amphipathic helical peptide, cecro-
pin, will dissipate a transmembrane electrochemical
gradient at a low peptide concentration but requires
a higher concentration to a¡ect the release of an
encapsulated £uorescent probe [3]. This peptide is
cytotoxic to Gram-negative bacteria at low concen-
trations which dissipate ion gradients but which are
not su⁄cient to cause the release of cytoplasmic con-
tents [3]. Some of these possible mechanisms will be
discussed in more detail below.
2. Amphipathic and hydrophobic K-helices
Perhaps one of the larger and better studied classes
of bacteriostatic peptides are those that form cationic
amphipathic helices [4]. However, there are also K-
helical peptides that are hydrophobic or even slightly
anionic. Peptides which are not cationic exhibit less
selectivity towards microbes compared with mamma-
lian cells. An example of a well-studied hydrophobic
and negatively charged cytotoxic peptide is alamethi-
cin. This helical peptide forms clusters of helices that
traverse the bilayer and surround an aqueous pore
which can transport ions [5]. Another peptide that is
hydrophobic and forms a helical transmembrane
structure is gramicidin A. In membranes, it forms a
cation-selective right-handed helix that traverses the
membrane as a single-stranded head-to-head dimer
[6] (Fig. 1). Both alamethicin and gramicidin are syn-
thesized by microorganisms by a mechanism that
does not involve ribosome synthesis. Since these pep-
tides exhibit little selectivity for microbial mem-
branes, their usefulness as speci¢c pharmacological
agents is limited. The majority of the cytotoxic am-
phipathic helical peptides are cationic and they do
exhibit selective toxicity for microbes.
One of the most studied of the cationic, antimicro-
bial, amphipathic helical peptides is magainin. This
23 amino acid peptide is secreted on the skin of the
African clawed frog, Xenopus laevis [7]. The proper-
ties of this peptide have recently been reviewed [8,9].
From these studies, the concept of a lytic pore has
developed. This pore di¡ers in a number of respects
from the type of pore formed by helical clusters of
peptides, such as that of alamethicin. In the case of
Fig. 1. Structure determined by solid state NMR for the pep-
tide gramicidin A [6] in oriented membranes. A shows a peptide
dimer traversing the membrane, with the four Trp side-chains
anchoring the peptide to the membrane interface. B shows a
space-¢lling structure, a 90‡ rotation compared to A reveals the
hole down the center of the peptide (¢gures drawn with the
program SETOR [152] from the protein database (PDB) entry
IMAG).
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magainin, the pore is larger and it does not have
discrete open and closed states as conducting pores
do. At the same time, the formation of this kind of
pore does not result in complete lysis of the mem-
brane. For example, magainin does not allow for the
passage of trypsin, a protein of 24 kDa [10]. In ad-
dition, unlike the alamethicin pore which is lined
with only peptide, the wall of the pore formed with
magainin contains both lipid and peptide. Evidence
for this comes from the fact that magainin stimulates
the transbilayer movement of both peptide and lipid.
The promotion of positive membrane bilayer curva-
ture would be expected to facilitate the formation of
a peptide- and lipid-lined pore and this is what has
been found with magainin [11,12]. However, it has
also been observed that the model peptide 18L,
which has a consensus sequence for lytic peptides,
promotes negative curvature, as does the wasp ven-
om peptide mastoparan [13]. The cyclic peptide, gra-
micidin S, promotes the formation of structures
which give rise to isotropic 31P NMR spectra, which
may include the formation of inverted cubic phases
[14]. At least for zwitterionic membranes, leakage
caused by peptides that promote negative curvature
is more rapid with bilayers having a negative curva-
ture strain [15]. Current models of the large mem-
brane pores formed by some antimicrobial peptides
propose that the pore is lined with both peptide and
lipid. The phospholipid in these pores would have a
positive curvature and therefore, peptides that facili-
tated formation of structures with this curvature
would facilitate pore formation. However, the mech-
anism by which peptides promoting negative curva-
ture induce leakage is less well established. It could
simply be explained by the pore which is formed
being of a small diameter. The dependence of the
curvature of a toroidal pore on its diameter is a
consequence of the fact that there are two curvatures
to consider. One is along the bilayer normal, which
predominates in large pores, and the other is in the
plane of the bilayer, which is of opposite sign and
which predominates in small pores.
The importance of the amphipathic helical confor-
mation (Fig. 2) to the cytotoxic activity of magainin
was indicated by the ¢nding that replacement of sev-
eral amino acid residues in the peptide by their
D-isomers resulted in loss of helicity and of antimi-
crobial activity [16]. However, the importance of an
amphipathic helical conformation to the cytotoxic
action of peptides was questioned in similar studies
with the peptide pardaxin. Pardaxin is an amphi-
pathic helical peptide that shows lytic activity with
both microbial and mammalian cells. Incorporation
of some D-amino acid residues into pardaxin con-
verts the peptide conformation from an K-helix to
a L-structure [17]. The modi¢ed pardaxin with
L-structure lost hemolytic activity but retained anti-
microbial activity [17]. Thus, the conformational
property of an amphipathic K-helix is not required
for the antimicrobial activity.
3. L-Sheet peptides and small proteins
Helical peptides can exist in a membrane environ-
ment as a monomer with the hydrogen-bonding ca-
pacity of the amide groups ful¢lled. In order for this
to occur with L-structure peptides, a monomer must
aggregate or form a bend to allow for an intramo-
lecular anti-parallel L-structure to form. The latter
situation is not likely to occur with small peptides
because the loss in entropy would not be compen-
sated by the favorable bonding interactions that
would result. In addition, such a monomeric L-struc-
ture with only two interacting peptide segments
would still have half the hydrogen-bonding potential
of the amide groups unful¢lled. Many of the antimi-
crobial peptides which form a L-structure are able to
do so because they are cyclical peptides and hence,
Fig. 2. Structure of the antimicrobial frog skin peptide magai-
nin as determined by NMR spectroscopy in the presence of
SDS micelles [125]. The structure was generated using the pro-
gram SETOR [152] from the protein database entry 2MAG.
The side-chains of Lys and Phe residues are indicated, illustrat-
ing the cationic amphipathic nature of the structure.
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there is less entropy loss on formation of a L-struc-
ture. The ring structure is formed either by disul¢de
bonds, as in the case of the tachyplesins, protegrins
and lactoferricin (Fig. 3), or by cyclization of the
peptide backbone, as in the case of gramicidin S,
polymyxin B or the tyrocidines. The interaction of
gramicidin S with membranes is reviewed elsewhere
in this issue. Less is known about the mechanism by
which this class of antimicrobial peptides produces
membrane damage. A study of the orientation of
protegrin in membranes using oriented circular di-
chroism has demonstrated that there are two di¡er-
ent states of insertion of the peptide into a mem-
brane that depend on the peptide concentration, on
the nature of the lipid and on the extent of hydration
[18]. The peptide tachyplesin, which has a cyclic anti-
parallel L-sheet structure held together by two disul-
¢de bonds, permeabilizes both bacterial and arti¢cial
lipid membranes. It also translocates across lipid bi-
layers and this translocation is coupled with transient
pore formation [19], suggesting that it acts on the
cytoplasmic membrane in a similar manner as the
K-helical magainin. The critical parameter associated
with the antimicrobial action of this peptide appears
to be the maintenance of a certain hydrophilic-hy-
drophobic balance [20].
The e¡ect of substitution of D-amino acid residues
in a cyclic L-structure peptide, based on the sequence
of gramicidin S, was determined [21]. The L-structure
conformation adopted by this peptide in aqueous
solution was disrupted by the substitution of D-ami-
no acid residues. The amphipathic nature of the pep-
tide analogues was assessed by their retention time in
reversed phase high performance liquid chromatog-
raphy. Peptides with a high amphipathicity exhibited
high hemolytic activity but low antimicrobial activ-
ity. Those with a low amphipathicity, past a certain
threshold, exhibited higher antimicrobial activity.
Improvement in the therapeutic index as much as
10 000-fold was noted for some of these analogues
[21]. These results suggest that optimizing peptide
incorporation into the membrane may not always
produce the most e¡ective antimicrobial agents, but
that the interaction of the positive charges on the
peptide with the negative charges on the bacterial
membranes is important for antimicrobial activity.
This is similar to the ¢ndings with paradaxin quoted
above [17].
Defensins are a group of small proteins of about
50 amino acids that have a potent antimicrobial ac-
tivity. They are produced and stored in the granules
of neutrophils, where they form a part of the innate
immune system. They have been described in mam-
mals, insects and plant tissues. In the latter case, they
are commonly referred to as thionines. They have a
high number of disul¢de bonds that help to maintain
their structural integrity. The structures of several of
these small proteins have been solved and all possess
a L-sheet structure. The plant and insect defensins
also contain an additional K-helical structure motif
(see Fig. 4). All defensins have amphipathic struc-
tures that probably allow them to act on bacterial
membranes in a similar manner as the shorter am-
phipathic peptides [22].
Fig. 3. The 20 best structures determined by proton NMR for the irregular L-sheet structure of lactoferricin B in aqueous solution
[105]. The Trp, Phe, Ile and Pro residues, form the hydrophobic face of the amphipathic structure. The Lys and Arg sidechains on
the opposite face of the structure (not shown) make up the positively charged surface. The position of the single disul¢de bond is also
indicated. These structures were generated using INSIGHTII (Molecular Simulations), from the protein database entry 1LFC.
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4. Peptides with irregular amino acid composition
Certain antimicrobial peptides have an unusual
amino acid composition, having a sequence which
is rich in one or more speci¢c amino acids. For ex-
ample, the peptide histatin, which is produced in
saliva, is extremely rich in His residues [23^25]. Other
peptides are produced by porcine neutrophils which
are very rich in proline and arginine or proline and
phenylalanine. These are called PR-39 and prophe-
nin, respectively, and they are part of the cathelicidin
family of antimicrobial peptides (see below).
Tryptophan is generally not an abundant amino
acid residue in peptides or proteins. This amino
acid is of particular interest with regard to the par-
titioning of peptides into membranes because of its
propensity to position itself near the membrane/
water interface [26,27]. Examples of antimicrobial
peptides which are rich in Trp include tritrpticin
(VRRFPWWWPFLRR) [28] and indolicidin
(ILPWKWPWWPWRR-amide) [29]. Indolicidin ap-
pears to permeabilize bacteria without lysing them
[30] and this peptide can form conductance channels
[31]. The formation of conductance channels suggests
that indolicidin can self-associate and that the hemo-
lytic activity of this peptide is associated with the
concentration required for its self-association [32].
5. Peptides with thio-ether rings
There are several peptides made by bacteria which
contain small ring structures enclosed by a thio-ether
bond. This group of peptides is called lantibiotics
and their structure and properties have recently
been reviewed [33,34]. One of the lantibiotics, nisin,
is currently used as an antimicrobial agent for food
preservation. The properties of this peptide are re-
viewed in this issue [35]. It has been found that nisin
rapidly induces leakage of ions and small metabolites
from bacteria [36] and opens electrical conductance
channels in black lipid membranes [37,38]. The mo-
Fig. 4. Structures determined for several defensins ribbon dia-
grams are shown, with disul¢de linkages in ball and stick repre-
sentations. (A) Defensin HNP-3, (B) purothionine, (C) insect
defensin A (PDB: 1ICA). This ¢gure is taken from [117] with
permission from NRC Press.
6
BBAMEM 77742 25-11-99 Cyaan Magenta Geel Zwart
R.M. Epand, H.J. Vogel / Biochimica et Biophysica Acta 1462 (1999) 11^2816
lecular details of the mechanism by which nisin
breaks down the membrane permeability barrier is
not well understood [39]. However, there have been
a number of studies which indicate the groups which
are important for the antimicrobial action of this
peptide and for the insertion of this peptide into a
membrane. Unlike most antimicrobial peptides,
which discriminate among lipids largely on the basis
of charge interactions, certain lantibiotic peptides,
such as cinnamycin, have speci¢city for phosphatid-
ylethanolamine [40]. Electrostatic interactions are im-
portant, however, for the initial binding of nisin to
membranes containing anionic lipids [41]. The posi-
tively charged C-terminal domain of the peptide is
important for this binding. This conclusion is sup-
ported by experiments on the £uorescence properties
of Trp substituted in this region of the molecule
[42,43]. Other regions of the peptide are also inserted
into the membrane, suggesting an initial parallel ori-
entation of the peptide to the membrane surface [43].
This is also supported by NMR evidence, suggesting
that the peptide remains at the surface of dodecyl-
phosphocholine micelles [44]. However, results of ex-
periments with trypsin entrapped within vesicles sug-
gest that there is a transient insertion of the C-
terminal region of the peptide [45]. It was found
that the pH dependence of this insertion paralleled
the permeabilization of the membrane, suggesting
that a membrane pore was formed as a consequence
of the insertion of this region of the peptide into a
membrane [45]. Conductivity studies indicate that the
insertion of the peptide into the membrane follows
surface association [46]. It has also been observed
that a higher pH leads to higher leakage rates of
liposomal contents as a result of a small number of
nisin molecules being required to induce leakage [47].
This may be a consequence of less charge on the
peptide at a high pH, facilitating greater self-associ-
ation. In this and other cases, there may be a di¡er-
ence between the position of the peptide in a mem-
brane in its most stably inserted form and the
arrangement which is responsible for its membrane
activity.
6. Peptaibols
These peptides are characterized by having a high
proportion of K-amino-isobutyric acid (Aib) resi-
dues. These residues are conformationally restricted
and favor the formation of K-helical and in particu-
lar, 310 helical structures, even in the case of the
solution conformation of the short antimicrobial
peptide trichogin [48]. In addition, these peptides
are lipopeptides which are acylated at the N-termi-
nus, thus favoring their partitioning into membranes.
(Attachment of short fatty acid chains occurs more
frequently in peptides produced by microorganisms:
note that polymyxin B is also acylated.) This group
of peptides derives their name of ‘peptaibols’ from
the fact that they have a 1,2-amino alcohol at the C-
terminus. There have been many studies on the pep-
taibol alamethicin, which forms membrane channels
through self-association into a ring of transmem-
brane helices. Another, less studied peptaibol is tri-
chogin GA IV, which has the sequence N-octanoyl-
Aib-Gly-Leu-Aib-Gly-Gly-Leu-Aib-Gly-Ile-Lol. The
membrane is a likely site of action of trichogin, since
this lipopeptide is sparsely soluble in water, contains
an octanoyl anchor and is devoid of charged groups.
Two of the ways this lipopeptide can insert into
membranes are with the helix axis either largely per-
pendicular or largely parallel to the plane of the bi-
layer. Channel-forming cytotoxic peptides, such as
alamethicin, form clusters of helices parallel to the
bilayer normal. This is not a likely motif for the
interaction of trichogin with membranes. X-ray dif-
fraction studies of trichogin crystals show that the
length of the helix is only about 16 Aî [49]. Trichogin
is thus too short and would not span a membrane
bilayer in a helical conformation. However, there
may be a transient, higher energy state of the peptide
which is more deeply inserted into the membrane and
which causes leakage.
7. Macrocyclic cystine knot peptides
As indicated before, several antimicrobial peptides
have a cyclic peptide structure, with usually less than
15 amino acids involved. Recently, four macrocyclic
end-to-end 30 amino acid residue cyclic peptides
from plants of the Rubiacease family were found to
possess potent antimicrobial activity [50]. These four
proteins (kalata, circulin A and B and cyclopsycho-
tride) also have a cystine knot motif, where the knot-
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ted motif arises because one disul¢de bond is
threaded through the other two. This structural mo-
tif is also found in protease inhibitors and toxins
and, together with the cyclic backbone, confers a
high rigidity to the structure. Structures for two of
these proteins have been reported [51,52]. Circulin A
and B have been shown to have anti-viral activity as
well [53] and may play a role as an anti-HIV drug.
8. Role of membrane lipids
Biological membranes contain a large variety of
lipids, hence most of our knowledge of the roles of
speci¢c lipid properties comes from studies of model
membranes. One property of these membranes that
has been associated with antimicrobial speci¢city is
their negative charge. Several antimicrobial peptides
are cationic and preferentially bind to anionic lipids.
This can provide a potential mechanism for micro-
bial speci¢city, since most of the anionic lipids of
mammalian membranes are sequestered on the cyto-
plasmic side of the membrane while they are exposed
to the external medium with microbial membranes.
In addition to the aspect of microbial speci¢city, it is
possible that the interaction of cationic peptides with
membranes causes a preferential sequestering of the
anionic lipids, leading to less regularly packed boun-
daries between domains rich in anionic lipids and the
remainder of the membrane. Studies with £uores-
cence-labelled lipids demonstrated that a model cat-
ionic peptide can attract small clusters of anionic
lipid [54], although it is unclear at present whether
this clustering phenomenon plays a role in their anti-
bacterial e¡ects. It has been shown that liposomal
leakage induced by magainin is very sensitive to the
nature of the anionic lipid [11]. It is interesting that
this peptide is much more e¡ective in inducing leak-
age in liposomes of phosphatidylglycerol, a lipid with
a high abundance in microbial membranes, than in
liposomes of phosphatidylserine, the major anionic
lipid of mammalian membranes. These ¢ndings also
suggest that other properties, in addition to mem-
brane charge, determine the rate of leakage caused
by these peptides. One of these factors is membrane
curvature [11,15,55]. However, knowledge of the ef-
fects of antimicrobial peptides on curvature is not
su⁄cient to predict the potency or antimicrobial spe-
ci¢city of these peptides, since peptides that increase
positive membrane curvature as well as those that
increase negative curvature can be lytic. However,
membranes with intrinsic negative curvature tend to
be lysed more readily by peptides that promote addi-
tional negative curvature [55].
9. The potential role of lipopolysaccharide (LPS) and
the bacterial outer membrane
All Gram-negative bacteria have LPS in the outer
lea£et of their outer membrane. LPS can be subdi-
vided in three speci¢c regions, the O-antigen, the
core and lipid A. Both O-antigen and the core con-
Fig. 5. Structure of a LPS molecule, as determined by X-ray
crystallography. A single LPS molecule was found non-cova-
lently bound to the outer membrane ferrichrome transporter
Fhu A in its crystal structure [153].
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sist of polysaccharide chains and protrude outwards
from the membrane surface. The major membrane
component, lipid A, is a complex molecule consisting
primarily of fatty acids and phosphate groups
bonded to a carbohydrate backbone (see Fig. 5).
The charge on the lipid A molecules is negative
and the outer membrane lea£et structure is held to-
gether in part by the binding of divalent cations.
Because electrostatic interactions are e¡ective over
relatively long distances, the charges on the bacterial
Gram-negative outer membrane make it an ideal tar-
get for binding cationic peptides. Many studies, in-
cluding theoretical quantum chemical calculations
[56], have shown that Arg side-chains and phosphate
groups in particular can form relatively stable inter-
actions.
Several studies of the interactions between cationic
antimicrobial peptides, such as magainin, cecropin
and polymyxin, and LPS have been reported. In
some of the earliest work, a correlation between
the a⁄nity of magainin for mutant strains of Salmo-
nella typhimurium and the depth of lesions in the
rough LPS was shown [57]. Also, the diphosphoryl
moiety of lipid A was shown to play a major role in
the binding of cecropin [58]. Moreover, it was dem-
onstrated by infrared spectroscopy that binding of
magainin can lead to disorder in the LPS [59].
More recently, similar results have been reported
for polymyxin binding to puri¢ed LPS [60,61] and
for magainin binding to de¢ned vesicles containing
LPS [62], as well as LPS derived from Yersinia ente-
rocolitica [63]. Based on these results, it seems likely
that the binding of cationic antimicrobial peptides to
the outer membrane could play a major role in their
toxicity towards the microorganisms. However, het-
erogeneity amongst various LPS preparations makes
it di⁄cult to directly compare the various studies
performed to date. Better de¢ned and standardized
preparations would allow for more detailed biophys-
ical studies of these interactions, which would lead to
a deeper understanding of the role of LPS. For ex-
ample, it has been suggested that cationic peptides
could displace the divalent cations, hence leading to
destabilization of the outer membrane. To date, di-
rect evidence for such a mode of action is lacking,
however. In some studies, serious disruption of the
outer membrane (e.g. membrane blebbing) has been
observed by electron microscopy [64^67] upon addi-
tion of cationic peptides such as polymyxin B, sug-
gesting that this may be su⁄cient to explain the anti-
bacterial action. However, not all antimicrobial
peptides appear to have such a dramatic e¡ect on
the morphology of the outer membrane (see below).
Be that as it may, even if the direct bacteriostatic
action of a cationic antimicrobial peptide is at the
level of the cytoplasmic membrane, peptides would
still have to ¢nd a way to cross the outer membrane
to gain access to the periplasmic space, from where
they can act on the cytoplasmic membrane. Given
the limited size of the opening in outer membrane
porin proteins, the most likely transfer mechanism
across the outer membrane involves direct binding
to LPS and subsequent transfer to the periplasm
[68,69] (Fig. 6).
In several molecular genetics studies, S. typhimu-
rium mutants have been uncovered that have an al-
tered sensitivity to cationic antimicrobial peptides.
Increased resistance to polymyxin B was shown to
correlate with extensive modi¢cation of LPS, in par-
ticular 31P NMR studies showed that modi¢cation of
the phosphate groups of LPS occurred, which gave it
a reduced negative charge [70^73]. Additional resist-
Fig. 6. Mechanism proposed for the transport of antimicrobial
peptides across the outer membrane of Gram-negative bacteria.
The initial recognition involves the negatively charged LPS on
the outer lea£et and the cationic peptide. Once entered into the
periplasmic space, the peptide can move to the cytoplasm mem-
brane (adapted from [68]).
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ant mutants have been described where the level of
acylation of lipid A was reduced and it was suggested
that this could block transfer of peptide across the
outer membrane [68,74]. These results again under-
score the importance of the lipid A portion of LPS in
the bacteriostatic action of cationic antimicrobial
peptides. They also show that it is possible to select
for resistant bacteria, suggesting that, like commonly
used antibiotics, resistance could eventually develop
against some of the bacteriostatic peptides as well. It
seems likely that binding to LPS plays a di¡erent role
with distinct cationic peptides. Enterobacteria that
had a defective outer membrane, and had become
resistant to polymyxin B, were still completely sus-
ceptible to cecropin B, indicating that both peptides
have di¡erent targets [75]. Likewise, defensins were
also fully active in strains with defective outer mem-
branes [76], suggesting that they do not act at the
outer membrane but at other structures such as the
cytoplasmic membrane.
Gram-positive bacteria such as Staphylococcus
aureus do not have an outer membrane or LPS,
but instead they possess a peptidoglycan as a com-
ponent of the surface membrane which is rich in
teichoic acid. Mutations leading to an increased neg-
ative surface charge in this structure also lead to an
increased sensitivity towards cationic antimicrobial
peptides [77], again illustrating the importance of
electrostatic interactions in their mechanism of ac-
tion.
Finally, it should be pointed out that clinically,
LPS and in particular lipid A play an important
role in the pathophysiology of Gram-negative bacte-
rial sepsis which leads to endotoxic shock, often cul-
minating in the death of the patient. In the USA
alone, the annual mortality is approximately
100 000 patients, a signi¢cant problem. In principle,
agents that can bind LPS which have been released
from bacterial cell walls in the bloodstream can neu-
tralize its toxic action. Indeed, vertebrates as well as
invertebrates have proteins in their circulatory sys-
tem which can bind to LPS and neutralize its endo-
toxin activity. The X-ray structures of some of these
proteins have recently been reported [78,79]. Since
various cationic antimicrobial peptides are known
to bind to LPS, they may have a role in treating
sepsis, providing yet another important rationale
for future biophysical studies in this area [60,61].
10. Alternative mechanisms of action
Studies with synthetic all-D antimicrobial peptides
are widely quoted as proof that many peptides act
directly on the membrane lipid bilayer, rather than
on a receptor protein. Indeed, the original studies
with K-helical peptides such as magainin, cecropin
and melittin showed that the all-D peptides were
equipotent to the naturally occurring all-L peptides
[80^83], making it unlikely that a highly stereospe-
ci¢c target, such as a membrane-bound protein re-
ceptor or a cytoplasmic enzyme, would be required
to mediate their bacteriostatic e¡ects. However, sub-
sequent studies with various other peptides have
shown that all-L and all-D enantiomer peptides are
frequently not of equal activity [82], moreover, the
results appear to be strongly species dependent. For
example, the ratio of lethal concentrations of L/D-iso-
mers for the proline-arginine-rich PR-39 peptide was
shown to be high for Pseudomonas aeruginosa
(L/D = 66) and S. aureus (L/Ds 1000), while no chiral
selectivity was observed with Escherichia coli or Ba-
cillus subtilis [82]. Also the enantiomers of the K-hel-
ical porcine cecropin P peptide showed di¡erences in
the sensitivity with these bacterial species [82]. In the
case of short 11 residue lactoferricin analogs, the
activity of the all-D peptide was markedly increased
over its naturally occurring analog when tested
against various bacteria [84]. On the other hand, D-
enantiomers of lysozyme-derived peptides were equi-
potent when tested against four bacterial strains, but
a lot less active than the L-derivative with ¢ve others
[85]. Perhaps, the di¡erent e¡ects on these bacterial
strains are related to di¡erences in their membrane
compositions. However, such results could also point
towards a stereospeci¢c complementarity between
the peptide and a bacterial ‘receptor’ molecule, at
least in certain bacterial species. The nature of such
molecules has remained elusive to date. However,
since many antimicrobial peptides seem to be capable
of spontaneously traversing bacterial outer and inner
membranes, the idea that they can act on an intra-
cellular target has some merit. There have been sug-
gestions made that DNA could be the target. Indeed,
the basic N-terminal region of lactoferrin, which con-
tains the antimicrobial peptide lactoferricin, has been
shown to bind to speci¢c regions of DNA, where it
may act to regulate transcription [86,87]. For PR-39,
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no lysis of E. coli has been observed, leading to the
suggestion that DNA and protein synthesis may be
terminated by this peptide [88]. In the case of the
lactic acid bacterial peptide leucocin and many of
its related peptides, the requirement for a mem-
brane-bound receptor protein as one potential key
molecular recognition event for antimicrobial activity
has been discussed [89]. Hopefully, such proteins, if
they exist, will soon be isolated, to help us to under-
stand their role in the mechanism of action of anti-
microbial peptides. Clearly, there could be di¡erent
mechanisms of action for di¡erent peptides and the
mode of action may, for a given peptide, also vary
among bacterial species.
11. Biosynthesis of antimicrobial peptides
Antimicrobial peptides in multicellular organisms
are found on external surfaces such as the skin or the
lungs or they are sequestered in granules of neutro-
phils, from where they can be released to attack a
pathogenic bacterium. Their synthesis is often in-
duced in response to an infection [90]. As such, these
peptides form an integral part of the innate immune
response [91]. The large majority of antimicrobial
peptides synthesized by multicellular organisms are
encoded by the genome. They are produced through
regular processes of gene transcription and ribosomal
translation, often followed by further proteolytic
processing of the gene product. Many antimicrobial
peptides produced by microorganisms contain un-
common amino acids. Several of these are not ribo-
somally synthesized or they are ribosomally synthe-
sized and subsequently modi¢ed. These are highly
speci¢c processes and we will not discuss the latter
group any further (for reviews, see [92,93]).
Magainins are synthesized as a long preproprotein
containing six copies of the peptide. Proteolytic proc-
essing leads to the release of the individual magainin
peptides [6,94]. Likewise, the 35^37 residues insect
cecropins are synthesized as preproproteins of 62
amino acids and processing involves several protease
activities [95,96]. Moreover, in many cationic antimi-
crobial peptides such as the cecropins, the negative
charge of the carboxyl terminus is removed by an
amidation process [97].
An interesting group of antimicrobial peptides are
the cathelicidins [98]. These all have a conserved pro-
region of about 100 amino acids resembling the pro-
tein cathelin, a member of the cysteine proteinase
inhibitor superfamily. Cathelicidins are stored in
the granules of leukocytes and they are released
upon activation of the leukocyte. However, they
have a remarkably di¡erent C-terminal antimicrobial
domain, encoding either L-sheet proteins such as pro-
tegrin or proline-arginine-rich and proline-phenylala-
nine-rich antimicrobial proteins (PR-39 and prophe-
nin) or short 13 residue tryptophan-rich peptides
(e.g. indolicidin and tritrpticin) or K-helical peptides
(CAMP OR LL37). The bovine, porcine and ovine
cathelicidins make up a multigene family. However,
in humans, the group only appears to have one mem-
ber, the K-helical LL37 peptide [98^101]. The latter
gene is also induced during in£ammatory disorders
[101].
Also the dermaseptins, a group of antimicrobial
peptides found in the skin of a variety of frog spe-
cies, constitute a family with a common preproregion
and a highly variable carboxy-terminal antimicrobial
domain. The peptides produced are either linear am-
phipathic K-helices or disul¢de-linked or short hy-
drophobic peptides [102]. Despite the diversity in
the structures of the antimicrobial peptides, they all
have very similar preproregions with a rather acidic
proregion following a regular signal peptide. The
high conservation of the precursor prepropart indi-
cates that this region must have an important func-
tion [102], as has also been suggested for the cathe-
licidins [98].
More recently, it has become apparent that several
cationic antimicrobial peptides can be released by
cleavage of intact proteins that may have no or lim-
ited antibacterial activity themselves. This has been
demonstrated ¢rst for the milk protein lactoferrin
[103]. Proteolytic cleavage of the intact bovine pro-
tein by pepsin under acidic conditions releases a 25
residue peptide (lactoferricin B), which shows a
markedly increased bacteriostatic potency compared
to the intact protein [103]. This region of the protein
contains many positively charged residues [104]. A
similar but less dramatic e¡ect is observed upon hy-
drolysis of the human lactoferrin protein [103]. It has
been shown that the increase in antimicrobial po-
tency of the peptide is probably related to a change
in the secondary structure giving rise to an amphi-
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pathic structure (Fig. 3), that seems ideally suited for
binding to the surface of negatively charged mem-
brane surfaces [105]. The alteration in the secondary
structure is rather dramatic, changing from a largely
K-helical structure in the protein to a distorted L-
sheet in the peptide [105]. When the peptide binds
to membrane mimetics, such as sodium dodecyl sul-
fate micelles, further changes occur in its structure
[106,107]. Somewhat surprisingly, most of the anti-
microbial activity of the lactoferrin-derived peptide
resides in a short hexapeptide comprising three Arg
and two Trp residues [108]. This result is consistent
with the outcome of combinatorial chemistry studies
of hexapeptides, which also revealed a high potency
for Trp and Arg-rich hexapeptides [109]. Such short
peptides could be of commercial interest and hence,
many short analogs of lactoferricin B have been syn-
thesized and tested for activity [84,110].
Other examples of antimicrobial peptides derived
from food proteins through proteolysis have been
reported. For example, it has been shown that heat
denaturation of hen egg white lysozyme generated an
antimicrobial activity in the unfolded protein that
was not related to its enzymatic activity [111]. Sub-
sequently, the bactericidal domain was isolated as a
peptide encompassing residues 98^112 of the intact
protein [85]. Also, the related viral T4 lysozyme has
an amphipathic C-terminal region that appears to
have membrane disrupting properties [112]. The ce-
cropin-like antimicrobial peptides produced by Heli-
cobacter pylori, the bacteria which colonizes the hu-
man stomach, were shown to be N-terminal
Fig. 7. Panel of structures showing the amphipathic nature of many antimicrobial peptides (reproduced with permission from NRC
Press from [117]). Connoly surface diagrams of several di¡erent antimicrobial peptides. The peptides are colored according to a hydro-
phobicity scale: blue represents the least hydrophobic residues (charged residues), whereas red represents the most hydrophobic resi-
dues. (a) The hydrophobic peptide surfaces. (b) The cationic surfaces.
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fragments of the ribosomal L1 protein [113]. Finally,
it should be pointed out that the highly cationic anti-
microbial peptides buforin I and parasin I are di-
rectly derived from the N-terminal domain of histone
H2A, a protein normally associated with the nucleo-
some [114,115]. This, taken together with the fact
that highly cationic nuclear protamines also bind
and dissolve the bacterial outer membrane [116],
may explain why in Japan, soft ¢sh roe, a by-product
of the ¢sh industry, can e¡ectively be used as an
antimicrobial substance to help in the preservation
of certain rice products.
12. Spectroscopic techniques to study peptide
membrane interactions
Amongst the experimental techniques used to
study the structure of antimicrobial peptides, high
resolution NMR spectroscopy occupies a prominent
position (for reviews, see [117,118]). With the excep-
tion of the defensins and thionines, for which the
crystal structure can be solved by X-ray methods
(e.g. [119]), the majority of the peptides are small
and £exible and hence, they resist attempts at crys-
tallization. Moreover, X-ray crystallography is gen-
erally not suitable for studying peptide-membrane
interactions, although some progress is being made
in this area [120]. Neutron di¡raction can also be
used to glean information about peptide-membrane
interactions [121^123]. However, this technique does
not yet provide high resolution structural informa-
tion. This leaves NMR spectroscopy as a major tech-
nique that can be utilized to obtain insight into the
three-dimensional structure of antimicrobial peptides
in solution or bound to membrane mimetics (Fig. 7)
[117,124]. Solid state NMR studies aimed at solving
the secondary structure and the orientation of pep-
tides with respect to oriented model membranes are
described by B. Bechinger in this issue and will not
be further discussed here.
The relatively small size of the antimicrobial pep-
tides makes them in principle ideal targets for high
resolution NMR studies. Generally, application of
routine two-dimensional proton NMR methods
[124], followed by structure calculations, is su⁄cient
to provide insight into the structure. The NMR spec-
tra are relatively simple and can be assigned using
proton total correlation experiments. Subsequently,
as many nuclear Overhauser e¡ect crosspeaks as pos-
sible are analyzed to provide distance restraints.
These can be supplemented with restraints for bond
angles as derived from NMR coupling constants.
Generally, distance geometry or restrained molecular
dynamics simulated annealing protocols are used to
calculate the three-dimensional structure.
For many shorter peptides, it was shown that in an
aqueous environment, these peptides have no de¢ned
structure. For example, typical amphipathic K-helical
peptides such as magainins and cecropins are un-
structured in aqueous solution [125^127]. Similar re-
sults are obtained with bacterially synthesized pep-
tides such as nisin and leucocin [128,89]. In contrast,
small L-sheet peptides, such as tachyplesin, protegrin
and lactoferricin B, seem to already form a more or
less de¢ned amphipathic sheet structure in aqueous
solution. The presence of one or two disul¢de link-
ages may help to stabilize these structures [129^131].
Other peptides, such as the proline-arginine-rich and
proline-phenylalanine-rich peptides, have resisted de-
tailed structural analysis by NMR to date. Their
spectra su¡er from serious spectral overlap because
of their unusual amino acid compositions.
The structure of peptides in solution can be ma-
nipulated by adding organic co-solvents such as tri-
£uoroethanol or hexa£uoroisopropanol [132]. These
agents induce a secondary structure in the peptide
that is thought to resemble that of the peptide bound
to the membrane [125,126]. Ideally, one would solve
the structure of a membrane-bound peptide directly,
but this is not possible with current solution NMR
methods. Membranes move very slow on the time
scale of the NMR experiment, leading to broad un-
resolvable resonances in the spectra. Therefore, it has
been customary to resort to the use of small mem-
brane mimetics, such as micelles, to study the struc-
ture of peptides bound to membranes [133,134]. Mi-
celles are formed spontaneously by putting detergent-
like molecules such as sodium dodecyl sulfate (SDS)
or dodecyl phosphorylcholine (DPC) in aqueous sol-
ution. They are known to be able to induce a second-
ary structure in bound peptides [135]. They have a
highly curved surface, making them not ideal substi-
tutes for a relatively £at bilayer surface. Larger
vesicles would be preferred, but these again would
give NMR lines that are too broad to analyze. The
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recently introduced bicelles may o¡er an alternative
[136], but so far, no detailed studies of bicelle-bound
antimicrobial peptides have been reported. Hence,
the determination of all high resolution NMR struc-
tures of membrane-bound antimicrobial peptides has
relied on the use of SDS and/or DPC micelles. Be-
cause of its overall negative charge, SDS may be a
good mimetic for bacterial membranes, while DPC is
related to the zwitterionic headgroups that make up
the majority of the outer lea£et of mammalian mem-
branes. To date, to our knowledge, no NMR studies
of peptides bound to LPS have been reported. Given
the importance of such interactions, as described
above, more work in this area is warranted in the
future.
It is important to recall that the structures of many
antimicrobial peptides di¡er when bound to a mem-
brane mimetic or in solution. In fact, many of them
only acquire a well-de¢ned three-dimensional struc-
ture upon binding to a membrane, including magai-
nin, cecropins [125^126] or Trp-rich peptides such as
indolicidin and tritrpticin (unpublished data). The
membrane-bound structures are all clearly amphi-
pathic with the hydrophobic amino acid side-chains
sequestered into the hydrophobic fatty acid portion
of the membrane, whereas the positively charged Arg
and Lys side-chains can interact with negatively
charged phosphodiester groups in the membrane in-
terface region (Fig. 2). Uniformly, all studies show
that all the cationic peptides bind in a parallel ori-
entation to the membrane surface, which has impli-
cations for their mode of action. While some infor-
mation can be obtained, it is di⁄cult to de¢ne
exactly the position of the peptide in the membrane.
Solid state NMR REDOR measurements have been
used to show that the peptide backbone amides of
magainin are bound near the phospholipid head
groups [137]. Also, nitroxide spin-labelled fatty acids
have been used. By varying the position of the nitro-
xide along the fatty acid chain, one can place the
nitroxide to a di¡erent depth in the membrane.
This perturbs NMR spectra in a predictable manner,
giving information on the position of the peptide
[106,138]. Most studies indicate a surface location
for bound peptides.
In addition to NMR, other lower resolution spec-
troscopic techniques, such as circular dichroism and
Fourier transform infrared spectroscopy, are useful
in studying the secondary structures of antimicrobial
peptides in solution and bound to membranes
[139,140]. Circular dichroism is particularly useful
to study the formation of an K-helical structure, be-
cause the prominent negative ellipticity observed at
208 and 222 nm that is associated with this structure
is easily observed. Infrared spectroscopy is often a
better choice for L-sheet structures, as these give a
signal that is generally more easy to distinguish from
random coils than K-helices. An advantage of these
spectroscopic techniques, as compared to NMR, is
that it is often possible to study more realistic mem-
brane mimetics, such as vesicles. Clearly, a combined
spectroscopic approach can provide the most de-
tailed information.
Another magnetic resonance method that has long
been used to study peptide-lipid interactions is elec-
tron paramagnetic resonance. For this type of sys-
tem, this method requires the introduction of a para-
magnetic species. This has generally been in the form
of a stable, sterically hindered nitroxide covalently
linked to one of the components of the lipid or pep-
tide molecule. The ¢rst applications of this method
have used nitroxide-labelled phospholipids to deter-
mine the number of lipids whose motional properties
are perturbed by the presence of a protein or peptide
[141]. The relative e¡ects of peptides in ordering dif-
ferent locations along the acyl chain can be moni-
tored by introducing spin labels at di¡erent positions
in the acyl chain. Spin labels have also been intro-
duced into speci¢c residues in proteins and peptides.
Often, the reactivity of cysteine residues has been
used to achieve this speci¢c labelling. Such studies
have been applied to determine the partitioning of
peptides between aqueous and lipid environments
[142], as well as to obtain information about the
nature of peptide and protein insertion into mem-
branes [143,144].
Fluorescence spectroscopy can be used to study
the insertion of intrinsic £uorophores such as trypto-
phan into membranes. Generally, a blue shift and an
increase of the quantum yield is obtained when the
Trp moves from a £exible, water-exposed position to
a more restricted position in the hydrophobic region
of the membrane [145]. Fluorescence quenching with
molecules such as iodide can provide insight into the
depth of Trp insertion into the membrane [145].
Also, the quenching e¡ect of nitroxide-labelled phos-
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pholipids on the Trp £uorescence can be used to gain
some insight into the depth of insertion of the pep-
tide [146,147]. Studies have shown that the Trp res-
idues of antimicrobial peptides are generally bound
close to the membrane head groups, in agreement
with its role as a membrane interface anchor
[26,27]. Kinetic information about the rate of the
peptide binding process can also be obtained by £u-
orescence spectroscopy [148]. A technique that is
gaining in prominence is surface plasmon resonance,
which makes it possible to study complex formation
and its on and o¡ rates in one direct measurement
[148].
Finally, it should be pointed out in this section
that NMR spectroscopy and infrared spectroscopy
both can be used to directly study the properties of
the membrane lipid bilayer in the presence and ab-
sence of the peptide. Such studies may help us to
gain an understanding of the changes in membrane
stability that accompany the binding and transport
of cationic antimicrobial peptides through the mem-
brane.
13. Summary
There are a wide variety of peptides with di¡erent
chemical structures and di¡erent peptide conforma-
tions which all exhibit antimicrobial activity. These
peptides, however, have certain properties in com-
mon. They all have a⁄nity for membrane lipids
and their speci¢city for microbial membranes in
many cases has been shown to be related to the pos-
itive charge on the peptide favoring interaction with
the exposed anionic lipids of microorganisms.
The mechanism by which these peptides kill cells is
less well understood in most cases. In particular, the
role of the membrane lipid bilayer in the biological
action of these peptides has become controversial.
There are several ways in which membranes may
be involved in the action of these peptides. The pep-
tides may form pores in the membrane allowing for
leakage of ions and other materials from the cell.
Alternatively, some of these peptides, such as ala-
methicin and gramicidin A, may form speci¢c ion
channels through the membrane. In addition, the
peptide may disrupt membranes by a ‘carpet-like’
mechanism, by which the association of the peptide
with lipid head groups destabilizes the membrane
[149]. However, the breakdown of the permeability
barrier in bacteria is not always closely correlated
with cytotoxic activity [2]. There are also other mem-
brane-dependent processes that may be involved in
the action of some of these peptides, including the
translocation of the cytotoxic peptide across the
membrane to the cytoplasm or the facilitation of
transbilayer lipid di¡usion leading to loss of lipid
asymmetry in the membrane. In addition, alternative
mechanisms have been proposed to explain the cyto-
toxic action of these peptides, including their stimu-
lation of autolytic enzymes [150], interference with
DNA and/or protein synthesis [30,80] or their bind-
ing to DNA [151]. However, one would anticipate
that many of these interactions would be similar in
mammalian cells and in microbes. Therefore, the
antimicrobial speci¢city of these peptides must
come from another source, such as di¡erences in
membrane interactions resulting in di¡erent rates of
transport of the peptides into cells. Given the diver-
sity of antimicrobial peptides and of target microor-
ganisms, it is not likely that there is one unique
mechanism for their mode of action. It would appear
that their interaction with membranes is an impor-
tant feature of these agents.
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